Figures S1-7 from Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer

Autor: Matthew J. Ellis, Cynthia X. Ma, Matthew N. Bainbridge, Shyam M. Kavuri, Dean P. Edwards, Shixia Huang, Shunqiang Li, Jeremy Hoog, John A. Olson, Kelly Hunt, Vera Suman, Jonathan T. Lei, Cheryl Schmidt, Jacob Schmelz, Meenakshi Anurag, Kimberly R. Holloway, Purba Singh, Nindo Punturi, Svasti Haricharan

Supplementary Figure 1 Mismatch repair dysregulation associates with high mutation load and poor clinical outcome in patients with ER breast cancer. Supplementary Figure 2 MutL complex disruption in ER breast cancer cells induces endocrine therapy re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05970a01cada46f0846e2266df7f4d18
https://doi.org/10.1158/2159-8290.22531617.v1

Data from A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer

Autor: Matthew J. Ellis, Charles Erlichman, Laurence Doyle, Malachi Griffith, Obi L. Griffith, Hussam Al-Kateb, Souzan Sanati, Kiran Vij, Ian S. Hagemann, Elaine Mardis, Kari B. Wisinski, Leslie Nehring, Zhanfang Guo, Jeremy Hoog, Kilannin Krysiak, Yan-Yang Feng, Zachary L. Skidmore, Erica K. Barnell, Tina Hieken, Charles Loprinzi, Timothy Moynihan, Tufia Haddad, Lee Wilke, Amye Tevaarwerk, Richard Gray, Rebecca Aft, Julie Margenthaler, Michael Naughton, Foluso Ademuyiwa, Mark E. Burkard, Donald Northfelt, Matthew P. Goetz, Vera Suman, Cynthia X. Ma

Purpose: Hyperactivation of AKT is common and associated with endocrine resistance in estrogen receptor–positive (ER+) breast cancer. The allosteric pan-AKT inhibitor MK-2206 induced apoptosis in PIK3CA-mutant ER+ breast cancer under estrogen-depri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::824ca18f79dabed32cbd89c9c0ffc7bd
https://doi.org/10.1158/1078-0432.c.6525357

Breast Density Knowledge and Awareness Among Latinas in a Low-Resource Setting

Autor: Bhavika K. Patel, Jennifer L. Ridgeway, Sarah Jenkins, Deborah J. Rhodes, Karthik Ghosh, Bijan Borah, Vera Suman, Aaron Norman, Jillian Leaver, Matt Jewett, Carrie Hruska, Crystal Gonzalez, Davinder Singh, Celine M. Vachon, Carmen Radecki Breitkopf

Publikováno v: J Am Coll Radiol

Latinas in low-resource settings face additional barriers to understanding mammographic breast density (MBD) implications. The authors compared MBD awareness and knowledge in Latinas from a safety-net clinic in Arizona with a national sample.Latinas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1ed5f8e5c83b7ae3822cb7c2255419c
https://doi.org/10.1016/j.jacr.2021.08.025

Abstract P6-05-38: Breast Density Notification: Impact on anxiety, breast cancer worry, and self-perceived risk among Latinas at a federally qualified medical center

Autor: Karthik Ghosh, Sarah Jenkins, Jennifer Ridgeway, Jessica D. Austin, Bijan Borah, Bhavika K. Patel, Deborah Rhodes, Aaron Norman, Edna P. Ramos, Matt Jewett, Crystal Gonzalez, Valentina Hernandez, Davinder Singh, Vera Suman, Celine Vachon

Publikováno v: Cancer Research. 83:P6-05

Mammographic breast density (MBD) has been shown to be a strong, independent risk factor for breast cancer (BC) irrespective of race/ethnicity. Given the risk association of MBD and its potential to mask tumors on a mammogram, state and federal laws

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::98480906714c741e4faa46dd2c44fe49
https://doi.org/10.1158/1538-7445.sabcs22-p6-05-38

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

Autor: Rosie Bradley, Jeremy Braybrooke, Richard Gray, Robert Hills, Zulian Liu, Richard Peto, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, Stewart Anderson, Richard Gelber, Luca Gianni, William Jacot, Heikki Joensuu, Alvaro Moreno-Aspitia, Martine Piccart, Michael Press, Edward Romond, Dennis Slamon, Vera Suman, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Fran Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Yaochen Wang, John Crown, Evandro de Azambuja, Suzette Delaloge, Helena Fung, Charles Geyer, Marc Spielmann, Pinuccia Valagussa, Kathy Albain, Rodrigo Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith Bliss, Etienne Brain, Lisa Carey, Robert Coleman, Jack Cuzick, Nancy Davidson, Lucia Del Mastro, Angelo Di Leo, James Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, Michael Gnant, Matthew Goetz, Pam Goodwin, Pat Halpin-Murphy, Dan Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori Pierce, Philip Poortmans, Vinod Raina, Daniel Rea, Meredith Regan, John Robertson, Emiel Rutgers, Tanja Spanic, Joseph Sparano, Guenther Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Tim Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Kathleen I Pritchard, Sandra M Swain

Publikováno v: The Lancet. Oncology
The lancet oncology
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) 2021, ' Trastuzumab for early-stage, HER2-positive breast cancer : a meta-analysis of 13 864 women in seven randomised trials ', The Lancet Oncology, vol. 22, no. 8, pp. 1139-1150 . https://doi.org/10.1016/S1470-2045(21)00288-6

Background: Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d82494828596b0011685b9eb25b23e93
http://europepmc.org/articles/PMC8324484